Quality of medical products for diabetes management: a systematic review

Background The global prevalence of diabetes mellitus is increasing alarmingly. However, the quality of vital medicines and medical products used to treat and monitor diabetes remains uncertain but of potential great public health significance. Here, we review the available evidence on the quality of antidiabetic medicines and supplies for self-monitoring of blood glucose (SMBG) and discuss their potential impact for the patients and society. Methods Searches were conducted in PubMed, Embase, Google Scholar, Google and relevant websites in English and French. The Medicine Quality Assessment Reporting Guideline (MEDQUARG) was used to assess the quality of medicine quality surveys. Results 52 publications on the quality of antidiabetic medicines, including 5 medicine quality prevalence surveys and 20 equivalence studies, were analysed. The prevalence surveys and equivalence studies included 674 samples of which 73 (10.8%) were of poor quality. The median (Q1–Q3) concordance with MEDQUARG items was 30.8% (19.2%–42.3%). No prevalence surveys on SMBG supplies’ quality were found, but 29 publications, including falsified products and incorrect results due to strip degradation or contamination, were identified. Conclusion There is little accessible evidence on the quality of antidiabetic medicines and SMBG supplies. Surveys were poorly designed and reported, making data aggregation and interpretation problematic. Despite these caveats, these results suggest that there are important issues with the quality of medical products for diabetes that need focused monitoring. There is an urgent need to achieve consensus protocols for designing, conducting and reporting medical product quality surveys. PROSPERO registration number CRD42016039841.

[1]  Medicines And Healthcare Products Regulatory Agency , 2020, Definitions.

[2]  S. Ozawa,et al.  Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries , 2018, JAMA network open.

[3]  P. Srinivas,et al.  Perceptions of the quality of generic medicines: implications for trust in public services within the local health system in Tumkur, India , 2018, BMJ Global Health.

[4]  É. Marijon,et al.  Fighting fake medicines: First quality evaluation of cardiac drugs in Africa. , 2017, International journal of cardiology.

[5]  N. Alam,et al.  A comparative in vitro dissolution of different brands of glibenclamide tablets available in Saudi Arabian market , 2017 .

[6]  Hazhar Karim,et al.  IN VITRO EQUIVALENCE EVALUATION OF FIVE DIFFERENT METFORMIN TABLET PRODUCTS USING UV SPECTROMETER , 2016 .

[7]  D. Moore,et al.  The global diabetes epidemic: what does it mean for infectious diseases in tropical countries? , 2016, The Lancet Diabetes & Endocrinology.

[8]  F. Sakr,et al.  Evaluation of the quality and pharmacoeconomics of some generic drugs versus their reputed counterpart brands in the Saudi market , 2016 .

[9]  Patricia Courselle,et al.  A simple dilute and shoot methodology for the identification and quantification of illegal insulin☆ , 2016, Journal of pharmaceutical analysis.

[10]  Gretchen A. Stevens,et al.  Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants , 2016, Lancet.

[11]  D. Beran,et al.  Constraints and challenges in access to insulin: a global perspective. , 2016, The lancet. Diabetes & endocrinology.

[12]  C. Gedeon,et al.  Counterfeit diabetes products and the ethical question of access , 2015 .

[13]  K. Aryal,et al.  Surveillance of Quality of Medicines Available in the Nepalese Market: A Study from Kathmandu Valley. , 2015, Journal of Nepal Health Research Council.

[14]  P. Newton,et al.  Responding to the Pandemic of Falsified Medicines , 2015, The American journal of tropical medicine and hygiene.

[15]  Matthew E. Falagas,et al.  Substandard/Counterfeit Antimicrobial Drugs , 2015, Clinical Microbiology Reviews.

[16]  C. Ebenezer Pharmaceutical quality and policy in Nigeria : stakeholder perspectives and validation of the Mobile Authentication Service , 2015 .

[17]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[18]  S. Haidar,et al.  PHARMACEUTICAL QUALITY OF GENERIC SITAGLIPTIN TABLETS COMPARED WITH JANUVIA , 2014 .

[19]  E. Redwan,et al.  Cell factories for insulin production , 2014, Microbial Cell Factories.

[20]  F. Schifano,et al.  A systematic review of counterfeit and substandard medicines in field quality surveys , 2014 .

[21]  Patricia Tabernero,et al.  Mind the gaps - the epidemiology of poor-quality anti-malarials in the malarious world - analysis of the WorldWide Antimalarial Resistance Network database , 2014, Malaria Journal.

[22]  Tatiana Dilla,et al.  Adherence to Therapies in Patients with Type 2 Diabetes , 2013, Diabetes Therapy.

[23]  O. Oyetunde,et al.  In Vitro Equivalence Studies of Generic Metformin Hydrochloride Tablets and Propranolol Hydrochloride Tablets Under Biowaiver Conditions in Lagos State, Nigeria , 2012 .

[24]  P. Newton,et al.  How to achieve international action on falsified and substandard medicines , 2012, BMJ : British Medical Journal.

[25]  I. Adelaja,et al.  Comparative Evaluation of Physicochemical Properties of Some Commercially Available Brands of Metformin Hcl Tablets in Lagos, Nigeria , 2012 .

[26]  Won Chan Lee,et al.  Cost of Self-Monitoring of Blood Glucose in the United States Among Patients on an Insulin Regimen for Diabetes , 2012, Journal of managed care pharmacy : JMCP.

[27]  P. Newton,et al.  The Primacy of Public Health Considerations in Defining Poor Quality Medicines , 2011, PLoS Medicine.

[28]  Raffaella Ravinetto,et al.  Quality of medical devices and in vitro diagnostics in resource‐limited settings , 2011, Tropical medicine & international health : TM & IH.

[29]  I. Hamdan,et al.  Pharmaceutical Evaluation of Metformin HCl Products Available in the Jordanian Market , 2010 .

[30]  J. Rodríguez,et al.  Los medicamentos falsificados en Perú , 2010 .

[31]  Jan S Krouwer,et al.  A Review of Standards and Statistics Used to Describe Blood Glucose Monitor Performance , 2010, Journal of diabetes science and technology.

[32]  S. Kao,et al.  An unusual outbreak of hypoglycemia. , 2009, The New England journal of medicine.

[33]  M. M. Cheng Is the Drugstore Safe? Counterfeit Diabetes Products on the Shelves , 2009, Journal of diabetes science and technology.

[34]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[35]  P. Newton,et al.  Guidelines for Field Surveys of the Quality of Medicines: A Proposal , 2009, PLoS medicine.

[36]  M. Massi-Benedetti,et al.  Quality and behavior of glimepiride generics versus amaryl under stressed conditions. , 2007, Diabetes technology & therapeutics.

[37]  Paul N Newton,et al.  Counterfeit anti-infective drugs. , 2006, The Lancet. Infectious diseases.

[38]  Alastair Gray,et al.  Economic burden of cardiovascular diseases in the enlarged European Union. , 2006, European heart journal.

[39]  J. Concato,et al.  Long-term glycemic control and postoperative infectious complications. , 2006, Archives of surgery.

[40]  L. Buhse,et al.  Quality assessment of internet pharmaceutical products using traditional and non-traditional analytical techniques. , 2005, International journal of pharmaceutics.

[41]  P. Newton,et al.  The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers , 2005, PLoS medicine.

[42]  A. Holstein,et al.  Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. , 2003, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[43]  J. Scarpello Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes: , 2001 .

[44]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[45]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[46]  A. Garber,et al.  Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. , 1997, The American journal of medicine.

[47]  FDA News , 1995 .

[48]  L. Groop Sulfonylureas in NIDDM , 1992, Diabetes Care.

[49]  M. Blaser,et al.  Campylobacter serology in patients with Chinese paralytic syndrome , 1991, The Lancet.

[50]  P. Wise,et al.  Detection of glibenclamide in oral insulin capsules , 1991, The Lancet.

[51]  T. Adrian,et al.  AUTOIMMUNITY IN DIABETICS INDUCED BY HORMONAL CONTAMINANTS OF INSULIN , 1979, The Lancet.

[52]  I. Leopold Editorial: Consolidation of United States Pharmacopeia and National Formulary. , 1974, American journal of ophthalmology.

[53]  A. Hirschfelder THE UNITED STATES PHARMACOPEIAL CONVENTION , 1930 .

[54]  A. Mitra Diabetes , 1894, The Indian medical gazette.

[55]  H. Fukuda,et al.  Impact of nonadherence on complication risks and healthcare costs in patients newly-diagnosed with diabetes. , 2017, Diabetes research and clinical practice.

[56]  M. Iwuagwu,et al.  A comparative evaluation of the pharmaceutical quality of different brands of metformin hydrochloride tablets available in Abuja , Nigeria , 2017 .

[57]  Vineet Kumar,et al.  Comparative in-vitro evaluation of four different brands of metformin HClavailable in Kanpur district, India , 2016 .

[58]  M. M. Gupta,et al.  In-vitro Pharmaceutical Quality Control Testing: a Comparative study of Different Brands of Metformin Tablets Available in the Trinidad & Tobago, West Indies , 2016 .

[59]  T. Ajala,et al.  The Pharmaceutical Quality of Brands of Metformin Tablets in Ogun-State, Nigeria , 2014 .

[60]  J. Bergquist,et al.  Pharmaceutical Evaluation of Type II Oral Antidiabetic Agent , 2014 .

[61]  Ramesh,et al.  A Comparative Analysis of Commercial Metformin Tablets. , 2014 .

[62]  P. Debnath,et al.  Analytical appraisement of some commercially available brands of Metformin Hydrochloride Tablet in Dhaka, Bangladesh , 2013 .

[63]  Dear Mr,et al.  Inspections, Compliance, Enforcement, and Criminal Investigations , 2012 .

[64]  S. Afifi,et al.  for Evaluation of Different Brands of Metformin Hydrochloride 500 Mg Tablets Marketed in Saudi Arabia , 2012 .

[65]  S. Muralidharan,et al.  Invitro studies and evaluation of metformin marketed tablets-Malaysia , 2011 .

[66]  J. Firth,et al.  Comprar Oxford Textbook of Medicine 5Ed | Edward J. Benz | 9780199204854 | Oxford University Press , 2010 .

[67]  Inspections , Compliance , Enforcement , and Criminal Investigations , 2009 .

[68]  James Ahlquist Oxford Textbook of Medicine , 1997, Journal of the Royal College of Physicians of London.

[69]  H. Blume,et al.  Pharmaceutical Quality of Glibenclamide Products A Multinational Postmarket Comparative Study , 1993 .

[70]  S. Lande Oxford Textbook of Medicine , 1983, The Yale Journal of Biology and Medicine.

[71]  G WhittakerP,et al.  共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値 , 1980 .